Reports
Sale
Encephalitis Market Size, Trends, Analysis, Forecast: By Type: Primary Encephalitis, Secondary Encephalitis; By Treatment: Antiviral Agents, Steroid Injection, Antibiotics, Immunoglobulin Therapy, Others; By Diagnosis; By Dosage; By Route of Administration; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Encephalitis Market Outlook
The encephalitis market size in the 7 major markets was valued at USD 20.85 billion in 2023, driven by the increasing incidence and awareness about encephalitis among people. The market size is anticipated to grow at a CAGR of 5.04% during the forecast period of 2024-2032 to achieve a value of USD 32.5 billion by 2032.
Encephalitis: Introduction
Encephalitis refers to the inflammation of the brain, stemming from various sources such as viral infections, autoimmune responses, bacterial infections, insect bites, and other triggers. The inflammation resulting from an infection within the brain is classified as infectious encephalitis. Conversely, when the immune system targets and inflames the brain, it is termed autoimmune encephalitis. At times, the cause remains unidentified. In certain instances, encephalitis can pose life-threatening risks. Swift diagnosis and treatment hold crucial significance due to the unpredictable nature of how encephalitis impacts everyone.
Encephalitis Market Analysis
The market growth is driven by significant developments in both pharmaceutical acquisitions and groundbreaking research. For example, Pfizer’s monumental acquisition of Seagen, aimed at diversifying its revenue streams amidst the anticipated decline in COVID-19 product sales and patent expirations, stands as a pivotal move. This acquisition not only provides Pfizer access to Seagen’s lucrative portfolio but also bolsters its already impressive range of approved oncological therapies, potentially influencing the treatment landscape for conditions like autoimmune brain inflammation. This acquisition may further develop a suitable and cutting-edge treatment therapy for better patient outcomes as Seagen is already familiar with the field, bolstering the encephalitis market growth.
Moreover, recent developments in research are further transforming the treatment landscape for autoimmune brain conditions such as encephalitis. For example, the innovative development of specialized CAAR-T cells designed to target and eliminate cells producing harmful antibodies, showcases promising strides in precision medicine. This innovative approach, exhibiting efficacy in preclinical models, signifies a potential development in treating autoimmune brain inflammation, a critical aspect of encephalitis. Such innovative developments are further expected to increase the encephalitis market demand.
Additionally, the emergence of a potential therapeutic agent for autoimmune encephalitis resulting from translational research is further expected to drive the market demand as it will result in more research for the treatment of the condition. This discovery brings hope for a targeted treatment option that could significantly impact the market.
Encephalitis Market Segmentations
Market Breakup by Type
- Primary Encephalitis
- Secondary Encephalitis
Market Breakup by Treatment
- Antiviral Agents
- Steroid Injection
- Antibiotics
- Immunoglobulin Therapy
- Plasmapheresis
- Others
Market Breakup by Diagnosis
- Imaging Tests
- Blood Tests
- Biopsy
- Others
Market Breakup by Dosage
- Injection
- Tablets
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Encephalitis Market Overview
The market is poised to witness substantial growth during the forecast period owing to various factors. The increasing prevalence of encephalitis worldwide, especially in the 7 major markets, coupled with determined efforts to enhance diagnosis and treatment options, is anticipated to be a major factor driving the market growth in the forecast period. The high mortality and morbidity rates resulting from the encephalitis virus signifies the urgent need for effective solutions, expected to increase the demand for effective treatment, therefore propelling the encephalitis market growth further. Initiatives supported by the government such as government-led vaccination programs are expected to play a pivotal role in stimulating market demand, exhibiting the will to approach disease prevention.
Moreover, the collaborative efforts of public and private organizations in awareness campaigns and the increased investment by the government are further expected to amplify the market reach. Factors such as a rise in disposable income, a burgeoning geriatric population, and evolving lifestyles are expected to further fuel market growth by increasing the demand for encephalitis treatments. Significantly, the surge in research and development activities, alongside substantial investments from both governmental and private sectors, are paving the road for further market growth.
Encephalitis Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Allergan
- Merck & Co.
- Pfizer Inc.
- GlaxoSmithKline plc
- Melinta Therapeutics LLC
- Basilea Pharmaceutica Ltd
- Abbott
- F. Hoffmann-La Roche Ltd.
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Cumberland Pharmaceuticals
- Fresenius Kabi AG
- Lupin
- AbbVie Inc.
- Endo International plc
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Treatment |
|
| Breakup by Diagnosis |
|
| Breakup by Dosage |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Encephalitis Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Encephalitis Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Encephalitis Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Encephalitis Epidemiology Forecast (2017-2032)
5.3.1 Germany Encephalitis Epidemiology Forecast (2017-2032)
5.3.2 France Encephalitis Epidemiology Forecast (2017-2032)
5.3.3 Italy Encephalitis Epidemiology Forecast (2017-2032)
5.3.4 Spain Encephalitis Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Encephalitis Epidemiology Forecast (2017-2032)
5.4 Japan Encephalitis Epidemiology Forecast (2017-2032)
6 Encephalitis Market Overview – 7MM
6.1 Encephalitis Market Historical Value (2017-2023)
6.2 Encephalitis Market Forecast Value (2024-2032))
7 Encephalitis Market Landscape-7MM
7.1 Encephalitis Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Encephalitis Product Landscape
7.2.1 Analysis by Diseases Type
7.2.2 Analysis by Treatments
7.2.3 Analysis by Route of Administration
8 Encephalitis Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Encephalitis Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Encephalitis Market Segmentation -7MM
11.1 Encephalitis Market by Type
11.1.1 Market Overview
11.1.2 Primary Encephalitis
11.1.3 Secondary Encephalitis
11.2 Encephalitis Market by Treatment
11.2.1 Market Overview
11.2.2 Antiviral Agents
11.2.3 Steroid Injection
11.2.4 Antibiotics
11.2.5 Immunoglobulin Therapy
11.2.6 Plasmapheresis
11.2.7 Others
11.3 Encephalitis Market by Diagnosis
11.3.1 Market Overview
11.3.2 Imaging Tests
11.3.3 Blood Tests
11.3.4 Biopsy
11.3.5 Others
11.4 Encephalitis Market by Dosage
11.4.1 Market Overview
11.4.2 Injection
11.4.3 Tablets
11.4.4 Others
11.5 Encephalitis Market by Route of Administration
11.5.1 Market Overview
11.5.2 Oral
11.5.3 Parenteral
11.5.4 Others
11.6 Encephalitis Market by Distribution Channel
11.6.1 Market Overview
11.6.2 Hospital Pharmacy
11.6.3 Retail Pharmacy
11.7 Encephalitis Market by Region
11.7.1 Market Overview
11.7.2 United States
11.7.3 EU-4 and the United Kingdom
11.7.3.1 Germany
11.7.3.2 France
11.7.3.3 Italy
11.7.3.4 Spain
11.7.3.5 United Kingdom
11.7.4 Japan
12 United States Encephalitis Market
12.1 Encephalitis Market Historical Value (2017-2023)
12.2 Encephalitis Market Forecast Value (2024-2032)
12.3 Encephalitis Market by Disease Type
12.4 Encephalitis Market by Treatment Type
13 EU-4 and United Kingdom Encephalitis Market
13.1 Encephalitis Market Historical Value (2017-2023)
13.2 Encephalitis Market Forecast Value (2024-2032)
13.3 Germany Encephalitis Market Overview
13.3.1 Encephalitis Market by Disease Type
13.3.2 Encephalitis Market by Treatment Type
13.4 France Encephalitis Market Overview
13.4.1 Encephalitis Market by Disease Type
13.4.2 Encephalitis Market by Treatment Type
13.5 Italy Encephalitis Market Overview
13.5.1 Encephalitis Market by Disease Type
13.5.2 Encephalitis Market by Treatment Type
13.6 Spain Encephalitis Market Overview
13.6.1 Encephalitis Market by Disease Type
13.6.2 Encephalitis Market by Treatment Type
13.7 United Kingdom Encephalitis Market Overview
13.7.1 Encephalitis Market by Disease Type
13.7.2 Encephalitis Market by Treatment Type
14 Japan Encephalitis Market
14.1 Encephalitis Market Historical Value (2017-2023)
14.2 Encephalitis Market Forecast Value (2024-2032)
14.2.1 Encephalitis Market by Disease Type
14.2.2 Encephalitis Market by Treatment Type
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Grants Analysis
16.1 Analysis by year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 Allergan
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisition
20.1.5 Certifications
20.2 Merck & Co.
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisition
20.2.5 Certifications
20.3 Pfizer Inc.
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisition
20.3.5 Certifications
20.4 GlaxoSmithKline plc
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisition
20.4.5 Certifications
20.5 Melinta LLC
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisition
20.5.5 Certifications
20.6 Basilea Pharmaceutica Ltd
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisition
20.6.5 Certifications
20.7 Abbott
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisition
20.7.5 Certifications
20.8 F. Hoffmann-La Roche Ltd.
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisition
20.8.5 Certifications
20.9 Mylan N.V.
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisition
20.9.5 Certifications
20.10 Teva Pharmaceutical Industries Ltd.
20.10.1 Financial Analysis
20.10.1 Product Portfolio
20.10.2 Demographic Reach and Achievements
20.10.3 Mergers and Acquisition
20.10.4 Certifications
20.11 Cumberland Pharmaceuticals
20.11.1 Financial Analysis
20.11.2 Product Portfolio
20.11.3 Demographic Reach and Achievements
20.11.4 Mergers and Acquisition
20.11.5 Certifications
20.12 Fresenius Kabi AG
20.12.1 Financial Analysis
20.12.2 Product Portfolio
20.12.3 Demographic Reach and Achievements
20.12.4 Mergers and Acquisition
20.12.5 Certifications
20.13 Lupin
20.13.1 Financial Analysis
20.13.2 Product Portfolio
20.13.3 Demographic Reach and Achievements
20.13.4 Mergers and Acquisition
20.13.5 Certifications
20.14 AbbVie Inc.
20.14.1 Financial Analysis
20.14.2 Product Portfolio
20.14.3 Demographic Reach and Achievements
20.14.4 Mergers and Acquisition
20.14.5 Certifications
20.15 Endo International plc
20.15.1 Financial Analysis
20.15.2 Product Portfolio
20.15.3 Demographic Reach and Achievements
20.15.4 Mergers and Acquisition
20.15.5 Certifications
21 Encephalitis Market - Distribution Model (Additional Insight)
21.1 Overview
21.2 Potential Distributors
21.3 Key Parameters for Distribution Partner Assessment
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 20.85 billion in 2023 in the 7 major markets, driven by the rising research and development.
The market is anticipated to grow at a CAGR of 5.04% during the forecast period of 2024-2032 and is likely to reach a market value of USD 32.5 billion by 2032.
The expanding healthcare industry, rising disposable incomes, and the increasing research and development activities are the major factors driving the market growth.
The introduction of a potential therapeutic agent, along with other innovative developments, are the major trends influencing the market growth.
The major regions of the market include United States EU-4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.
Types of encephalitis can be divided into primary and secondary.
Available treatments include antiviral agents, steroid injections, antibiotics, immunoglobulin therapy, and plasmapheresis, among others.
It can be diagnosed with the help of imaging tests, blood tests, and biopsies, among others.
Dosages could be injections and/or tablets, among others.
Oral and parenteral are the routes of administration in the market.
Distribution channels include hospital pharmacies and retail pharmacies.
Key players involved in the market are Allergan, Merck & Co., Pfizer Inc., GlaxoSmithKline plc,
Melinta LLC, Basilea Pharmaceutica Ltd, Abbott, F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Cumberland Pharmaceuticals, Fresenius Kabi AG, Lupin, AbbVie Inc., and Endo International plc.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER